Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage,
with systemic therapy being the mainstay of treatment. Survival continues to be limited …

Medical nanotechnology is surfacing as a challenging arena covering new biomedical
applications, such as drug delivery, treatment, nano diagnosis, controlled drug release …

Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in
clinics. We have developed a therapeutic HER2 siRNA delivered using mesoporous silica …

The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most
frequently the result of one of three gain-of-function substitution mutations of codon 12 …

All statements, findings, and conclusions in this publication are solely those of the authors
and do not necessarily represent the views of the Patient-Centered Outcomes Research …

Cancer is one of the deadliest form of diseases in humans, with the annual deaths ranging
in the millions. Conventional treatments including chemotherapy, radiotherapy, or surgery …